• 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-02
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Conclusion br In the current study we showed low


    In the current study, we showed low SES to be an independent predictor of adverse prostate cancer pathology in a DAPT of AA men treated with RP for clinically localized prostate cancer. By
    Clinical Genitourinary Cancer Month 2019 - 5
    Poverty and Adverse Prostate Cancer Pathology
    using a study design that included patients within a single racial demographic ethnicity, the confounding effects of race on prostate cancer risk were eliminated. These data suggest that impoverished men might be more likely to benefit from early prostate cancer detection and treatment. Community outreach, education, and screening efforts should therefore target low-income men for early intervention.
    Clinical Practice Points
    African American men are disproportionately affected by aggressive prostate cancer.
    We retrospectively reviewed data from 2 institutions for AA men who underwent RP and tested for associations between SES and adverse prostate cancer pathology after RP.
    Men of low SES had significantly higher PSA values and CAPRA-S scores, more advanced pathologic stage, and higher rates of SVI, positive surgical margins, and adverse pathology. These findings suggest that impoverished populations might benefit from more intensive screening and early, aggressive treatment of prostatic malignancies.
    The authors have stated that they have no conflicts of interest.
    3. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol 2010; 184:1931-6.
    4. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006; 106:1276-85. 5. Klein J, von dem Knesebeck O. Socioeconomic inequalities in prostate cancer survival: a review of the evidence and explanatory factors. Soc Sci Med 2015; 142:9-18. 6. RobbinsAS, WhittemoreAS,ThomDH.Differencesinsocioeconomicstatusandsurvival among white and black men with prostate cancer. Am J Epidemiol 2000; 151:409-16. 
    7. Cheng I, Witte JS, McClure LA, et al. Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California. Cancer Causes Control 2009; 20:1431-40.
    8. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992; 82:703-10.
    9. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Painting a truer picture of US socioeconomic and racial/ethnic health in-equalities: the Public Health Disparities Geocoding Project. Am J Public Health 2005; 95:312-23.
    10. Martinez EE, Forbes PW, O’Brien SE, de Ferranti SD. Census tract-based income level and lipid levels in urban pediatric primary care: a retrospective study. BMC Pediatr 2016; 16:86.
    11. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011; 117:5039-46.
    12. DeRouen MC, Schupp CW, Koo J, et al. Impact of individual and neigh-borhood factors on disparities in prostate cancer survival. Cancer Epidemiol 2018; 53:1-11.
    14. Hellenthal NJ, Parikh-Patel A, Bauer K, Ralph W, deVere W, Koppie TM. Men of higher socioeconomic status have improved outcomes after radical prostatectomy for localized prostate cancer. Urology 2010; 76:1409-13.
    15. Schwartz K, Powell IJ, Underwood W 3rd, George J, Yee C, Banerjee M. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 2009; 74:1296-302.